

**Amendments to the Specification**

**On page 1, please amend the paragraph starting on line 4 as follows:**

The present application is a U.S. National Phase Application of International Application PCT/US2002/036283, filed November 13, 2002, which ~~This application~~ claims the benefit of priority from U.S. Provisional Application No. 60/331,231 of the same title filed Nov. November 13, 2001, the entire disclosure disclosures of which are hereby is incorporated by reference in its entirety their entireties.

**On page 6, please amend the paragraph starting on line 17 as follows:**

In another embodiment, the invention provides a pharmaceutical composition comprising an effective amount of a polypeptide sequence of selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, biologically active fragments thereof, and variants thereof, and a pharmaceutically acceptable carrier. ~~The composition of claim 5, wherein~~ In one embodiment, the composition is a therapeutic or post-exposure prophylactic. Preferably, the composition is in the form of a vaccine.